Graduate School and Center Affiliations:
Associate Professor, Integrated Department of Immunology
Member, University of Colorado Cancer Center
Education:
Ph.D., Colorado State University, 1987
Postdoctoral Training:
NSF Postdoctoral Fellowship, University of California, Berkeley, 1987-1990
NIH Postdoctoral Fellowship, University of California, Berkeley, 1990-1993
We are studying
graft-versus-host disease (GVHD), which develops following hematopoietic stem
cell transplantation (HCT). A subset of T cells, called regulatory T
cells (Treg), can inhibit GVHD, but their global and relatively non-selective
capacity to suppress immune responses may compromise tumor and microbial
immunity. Using cord blood hematopoietic stem cells, we are
investigating human Treg development and migration in order to generate subsets
of Treg that have the capacity to traffic into specific tissues to reduce local
inflammation. With this strategy, suppression of inflammation in GVHD
targets, such as the intestine, liver, and skin, would not abrogate systemic
host immunity against deleterious antigens in non-affected organs.
Recent Publications
- Yingzhu Li, Nancy Clough, Xiaolin Sun, Weidong Yu, Brian L. Abbott, Christopher J. Hogan1, andZonghan Dai. Bcr-Abl induces abnormal cytoskeleton remodeling, 1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway. J. Cell Sci. 120: 1436-1446. 2007.
- Li, F.X., Zhu, J.W., Tessem, J.S., Beilke, J., Varella-Garcia, M., Jensen, J., Hogan, C.J., DeGregori, J. The development of diabetes in E2f1/E2f2 mutant mice reveals important roles for bone marrow-derived cells in preventing islet cell loss. Proc. Nat. Acad. Sci. (USA) 100: 12935-12940. 2003.
- Li, F.X., J.Z. Zhu, C.J. Hogan and J. DeGregori. Defective gene expression, S phase progression and maturation during hematopoiesis in E2F1/E2F2 mutant mice. Mol. Cell. Biol. 23: 3607-3622. 2003.
- Lacaud, G., Gore, L., Kennedy, M., Kouskoff, V., Palis, J., Kingsley, P., Speck, N., Hogan, C.J., Carlsson, L., Keller, G. Runx1 is required for hemangioblast development. Blood 100: 458-466. 2002
- Hogan, C.J., Shpall, E.J., Keller, G. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc. Nat. Acad. Sci. (USA) 99: 413-418. 2002.
- Shpall, E.J., Quinones, R., giller, R., Zeng, C., Baron, A.E., Jones, R.B., Bearman, S.I., Nieto, Y., Freed, B., Madinger, N., Hogan, C.J., Slat-Vasquez, V., Russell, P., Blunk, B., Schissel, D., Hild, E., Malcolm, J., Ward, W., McNiece, I.K. Transplantation of ex-vivo expanded cord blood. Biol. Blood Marrow Transplant 8: 368-376. 2002.
- Varella-Garcia, M., Hogan, C.J., Odom, L.F., Murata-Collins, J.L., Ai, H., Chen, L., fichkind, K., Paskulin, G., Andreeff, M., Brizard, A., McGavran, L., Gemmill, R.M., Berger, R., Drabkin, H.A. Minimal residual desease (MRD) in remission t(8;21) AML and in vivo differentiation detected by FISH and CD34+ cell sorting. Leukemia 15: 1408-1414. 2001.
- McNiece, I., Jones, R., Bearman, S., Cagnoni, P., Nieto, Y., Franklin, W., Ryder, J., Steele, A., Stoltz, J., Hartsough, K., Russell, P., McDermitt, J., Hogan, C.J., Murphy, J., Shpall, E.J. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery in breast cancer patients following high dose chemotherapy. Blood 96: 3001-3007. 2000.
- Hogan, C.J., Shpall, E.J., McNiece, I., Keller, G. Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells. Biol. Blood and Marrow Transpl. 3: 236-246. 1997.
- Hogan, C.J., Shpall, E.J., McNulty, O., McNiece, I., Dick, J.E., Shultz, L.D., Keller, G. Engraftment and development of human CD34+-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood 90: 85-96. 1997.
|
|